Company intelligence / Profile preview
KHR Biotech
Hamburg, Hamburg, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
KHR Biotech is a preclinical biopharmaceutical company with multiple programs targeting RAS signaling pathways currently in the discovery phase. The company is developing innovative therapeutic tools for cancer, with emphasis on colorectal cancer and RAS pathway mutations
- Therapeutic areas
- OncologyImmunologyRare DiseasesInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Indivumed GmbH (joint venture partner maintaining one of the world's largest tumor tissue and tumor databases)Evotec (colorectal cancer program partnership)
Beyond the preview
Go deeper on KHR Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KHR Biotech.